| 3.41 0.13 (3.96%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.08 |
1-year : | 4.77 |
| Resists | First : | 3.49 |
Second : | 4.08 |
| Pivot price | 3.13 |
|||
| Supports | First : | 3.1 |
Second : | 2.85 |
| MAs | MA(5) : | 3.27 |
MA(20) : | 3.1 |
| MA(100) : | 2.49 |
MA(250) : | 2.14 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 91.1 |
D(3) : | 86.7 |
| RSI | RSI(14): 70 |
|||
| 52-week | High : | 3.49 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARMP ] has closed Bollinger Bands are 4.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.5 - 3.53 | 3.53 - 3.55 |
| Low: | 3.1 - 3.12 | 3.12 - 3.14 |
| Close: | 3.38 - 3.42 | 3.42 - 3.45 |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Mon, 06 Oct 2025
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? - Yahoo Finance
Thu, 18 Sep 2025
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Mon, 08 Sep 2025
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology - PR Newswire
Thu, 04 Sep 2025
Bacteriophage Therapeutics Pioneer Armata Pharmaceuticals to Showcase Pipeline at Major Investment Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 1.104e+007 (%) |
| Held by Institutions | 70.2 (%) |
| Shares Short | 3 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.091e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 130.8 % |
| Return on Equity (ttm) | -25.1 % |
| Qtrly Rev. Growth | 3.72e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.18 |
| Dividend | 0 |
| Forward Dividend | 7030 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|